GCCL announced on Friday that it has signed a memorandum of understanding (MOU) with the Osong Advanced Medical Industry Promotion Foundation’s (KBIOHealth) New Drug Development Support Center. The agreement aims to contribute to clinical research and advance the pharmaceutical industry.
The signing ceremony took place at GCCL’s headquarters, with key attendees including Dr. Han Hye-jeong, Director of the New Drug Development Support Center, and Jo Kwan-goo, Chief Executive Officer (CEO) of GCCL, along with representatives from both organizations.
During the event, both parties reaffirmed their commitment to collaboration. They discussed establishing a practical link between research and development and clinical trial specimen analysis industries. This connection aims to ensure that new drug development research conducted in public facilities can smoothly progress to clinical stages.
The MOU outlines plans for the two organizations to strengthen the domestic clinical trial specimen analysis industry and new drug development ecosystem. They will collaborate on national research and development projects, and jointly develop educational programs to facilitate the exchange of technology, academic knowledge, and specialized personnel.
This partnership goes beyond typical institutional cooperation. It focuses on enhancing the competitiveness of the domestic new drug development ecosystem by combining the analytical capabilities of public research infrastructure with industry expertise.
The collaboration will integrate KBIOHealth’s public research infrastructure with GCCL’s experience in clinical trial specimen analysis and project execution. Both institutions aim to create a comprehensive support system that ensures technologies developed during research stages are effectively implemented in clinical trials.
CEO Jo emphasized the significance of this partnership, stating that collaborating with public new drug development support organizations is a crucial step in strengthening the research foundation of the domestic pharmaceutical and biotech industry. Through the partnership with the New Drug Development Support Center, it aims to elevate domestic research and development outcomes to achieve global clinical competitiveness.
